Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations
- PMID: 33241418
- DOI: 10.1093/eurheartj/ehaa845
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations
Abstract
Aims: Somatic mutations of the epigenetic regulators DNMT3A and TET2 causing clonal expansion of haematopoietic cells (clonal haematopoiesis; CH) were shown to be associated with poor prognosis in chronic ischaemic heart failure (CHF). The aim of our analysis was to define a threshold of variant allele frequency (VAF) for the prognostic significance of CH in CHF.
Methods and results: We analysed bone marrow and peripheral blood-derived cells from 419 patients with CHF by error-corrected amplicon sequencing. Cut-off VAFs were optimized by maximizing sensitivity plus specificity from a time-dependent receiver operating characteristic (ROC) curve analysis from censored data. 56.2% of patients were carriers of a DNMT3A- (N = 173) or a TET2- (N = 113) mutation with a VAF >0.5%, with 59 patients harbouring mutations in both genes. Survival ROC analyses revealed an optimized cut-off value of 0.73% for TET2- and 1.15% for DNMT3A-CH-driver mutations. Five-year-mortality was 18% in patients without any detected DNMT3A- or TET2 mutation (VAF < 0.5%), 29% with only one DNMT3A- or TET2-CH-driver mutations above the respective cut-off level and 42% in patients harbouring both DNMT3A- and TET2-CH-driver mutations above the respective cut-off levels. In carriers of a DNMT3A mutation with VAF ≥ 1.15%, 5-year mortality was 31%, compared with 18% mortality in those with VAF < 1.15% (P = 0.048). Likewise, in patients with TET2 mutations, 5-year mortality was 32% with VAF ≥ 0.73%, compared with 19% mortality with VAF < 0.73% (P = 0.029).
Conclusion: The present study defines novel threshold levels for clone size caused by acquired somatic mutations in the CH-driver genes DNMT3A and TET2 that are associated with worse outcome in patients with CHF.
Keywords: Chronic ischaemic heart failure; Clonal haematopoiesis; Epigenetic regulators TET2/DNMT3A.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Comment in
-
Clonal haematopoiesis and cardiovascular disease: how low can you go?Eur Heart J. 2021 Jan 20;42(3):266-268. doi: 10.1093/eurheartj/ehaa848. Eur Heart J. 2021. PMID: 33313787 No abstract available.
Similar articles
-
Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality.ESC Heart Fail. 2021 Jun;8(3):1873-1884. doi: 10.1002/ehf2.13297. Epub 2021 Mar 28. ESC Heart Fail. 2021. PMID: 33779075 Free PMC article.
-
Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction.EBioMedicine. 2022 Apr;78:103964. doi: 10.1016/j.ebiom.2022.103964. Epub 2022 Mar 24. EBioMedicine. 2022. PMID: 35339897 Free PMC article.
-
Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.JAMA Cardiol. 2019 Jan 1;4(1):25-33. doi: 10.1001/jamacardio.2018.3965. JAMA Cardiol. 2019. PMID: 30566180 Free PMC article. Clinical Trial.
-
Clonal haematopoiesis and dysregulation of the immune system.Nat Rev Immunol. 2023 Sep;23(9):595-610. doi: 10.1038/s41577-023-00843-3. Epub 2023 Mar 20. Nat Rev Immunol. 2023. PMID: 36941354 Free PMC article. Review.
-
Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to lymphoma.Crit Rev Oncol Hematol. 2025 Feb;206:104589. doi: 10.1016/j.critrevonc.2024.104589. Epub 2024 Dec 10. Crit Rev Oncol Hematol. 2025. PMID: 39667716 Review.
Cited by
-
How clonal hematopoiesis promotes inflammation at a single-cell level.Nat Cardiovasc Res. 2023 Sep;2(9):801-802. doi: 10.1038/s44161-023-00323-w. Nat Cardiovasc Res. 2023. PMID: 39196066 No abstract available.
-
Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID).Geroscience. 2025 Jun;47(3):2739-2775. doi: 10.1007/s11357-025-01654-1. Epub 2025 Apr 11. Geroscience. 2025. PMID: 40214958 Free PMC article. Review.
-
Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure.Clin Sci (Lond). 2021 Apr 16;135(7):991-1007. doi: 10.1042/CS20200306. Clin Sci (Lond). 2021. PMID: 33861346 Free PMC article. Review.
-
DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts.Nat Commun. 2024 Jan 19;15(1):606. doi: 10.1038/s41467-023-43003-w. Nat Commun. 2024. PMID: 38242884 Free PMC article.
-
A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential.Mol Biol Rep. 2023 Mar;50(3):2813-2822. doi: 10.1007/s11033-022-08118-1. Epub 2023 Jan 3. Mol Biol Rep. 2023. PMID: 36595120 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical